Global Point of Care Infectious Disease Market Size By Type (HIV POC, Clostridium difficile POC), By Application (Hospitals, Clinics), By Region, And Segment Forecasts, 2023 to 2032

The Global Point of Care Infectious Disease Market was valued at USD 8.2 billion in 2023 and is projected to surpass USD 14.5 billion by 2031, growing at a CAGR of 7.1% during the forecast period from 2023 to 2031. The market growth is driven by the increasing demand for rapid and accurate diagnostic solutions, rising prevalence of infectious diseases, and growing adoption of point-of-care (POC) testing in decentralized healthcare settings.

Point-of-care testing has gained significant traction due to its ability to deliver real-time diagnostic results, enabling early detection and effective management of infectious diseases such as HIV, tuberculosis, influenza, and COVID-19. The ongoing advancements in microfluidics, biosensors, and digital diagnostics are further enhancing the accuracy and efficiency of POC testing, fueling market expansion.

Drivers

Increasing Prevalence of Infectious Diseases

The rising incidence of infectious diseases, including respiratory infections, sexually transmitted infections (STIs), and emerging viral outbreaks, has created a heightened demand for rapid, on-the-spot diagnostic solutions. The need for timely diagnosis to prevent outbreaks and control disease spread is a key growth driver for the market.

Technological Advancements in POC Testing

Recent innovations in molecular diagnostics, lateral flow assays, and CRISPR-based diagnostic tools have significantly enhanced the accuracy, speed, and reliability of POC infectious disease testing. These advancements are making it easier for healthcare professionals to diagnose infections in resource-limited settings.

Growing Preference for Decentralized Testing

The shift towards decentralized healthcare models, including home-based, retail pharmacy, and community clinic testing, is expanding the market. The COVID-19 pandemic has further accelerated the adoption of self-administered and remote diagnostic testing solutions.

Restraints

Regulatory and Compliance Challenges

POC infectious disease tests must comply with strict regulatory approvals, including FDA, CE Mark, and WHO prequalification. The lengthy approval processes and stringent quality control measures pose challenges for market growth.

Limited Availability in Developing Regions

Despite the growing demand, accessibility to high-quality POC diagnostics remains a challenge in low-income countries due to cost constraints, lack of trained personnel, and inadequate healthcare infrastructure.

Opportunities

Expansion of POC Testing in Emerging Markets

The increasing investments in healthcare infrastructure and disease surveillance in Asia-Pacific, Latin America, and Africa offer significant growth opportunities for market players. Governments and global health organizations are promoting low-cost, portable, and easy-to-use diagnostics to improve early disease detection in remote areas.

Integration of AI and IoT in POC Diagnostics

The incorporation of artificial intelligence (AI) and the Internet of Things (IoT) in POC devices is enhancing connectivity, automation, and result accuracy. Smart diagnostic platforms can provide real-time data sharing, enabling better disease tracking and outbreak management.

Market by System Type Insights

Based on system type, the Molecular POC Testing segment accounted for the largest market share in 2023. Molecular diagnostics, such as PCR-based and isothermal amplification assays, provide higher sensitivity and specificity compared to traditional rapid tests, making them the preferred choice for detecting infectious diseases.

The Lateral Flow Assay segment is also witnessing significant growth due to its low cost, ease of use, and rapid turnaround time. These tests are widely used for detecting infections such as COVID-19, influenza, and malaria.

Market by End-Use Insights

Hospitals and Clinics Dominate Market Share

The Hospitals & Clinics segment emerged as the largest end-use sector in 2023, holding over 45% of the market share. The increasing need for quick diagnosis and treatment decision-making in hospital emergency departments and outpatient clinics is fueling demand for high-performance POC testing.

Home Care and Retail Pharmacies Gaining Traction

The Home Care and Retail Pharmacy segment is expected to register the fastest growth due to the rising trend of self-testing kits for infectious diseases. Companies are focusing on developing easy-to-use, over-the-counter (OTC) diagnostic kits that enable patients to test themselves at home, enhancing accessibility and affordability.

Market by Regional Insights

North America Leads the Global Market

North America dominated the global POC infectious disease market in 2023, accounting for the largest market share due to the high adoption of advanced diagnostics, strong regulatory frameworks, and presence of major industry players. The United States is the key contributor, with rising investments in rapid disease detection and personalized healthcare.

Asia-Pacific Witnessing Rapid Growth

The Asia-Pacific region is expected to grow at the highest CAGR during the forecast period, driven by rising healthcare awareness, government initiatives for disease surveillance, and increasing R&D investments in diagnostic technologies. Countries such as China, India, and Japan are leading this growth due to their expanding healthcare infrastructure.

Competitive Scenario

Key players operating in the Global Point of Care Infectious Disease Market include:

Abbott Laboratories

Siemens Healthineers

Roche Diagnostics

BioMérieux

Quidel Corporation

BD (Becton, Dickinson and Company)

Cepheid (a Danaher Company)

Thermo Fisher Scientific

Hologic, Inc.

LumiraDx

Recent Market Developments

In 2023, Abbott Laboratories launched a next-generation POC molecular diagnostic platform designed for rapid COVID-19 and influenza testing.

In 2023, Roche Diagnostics expanded its Liat PCR system, enhancing high-speed multiplex testing capabilities for respiratory and sexually transmitted infections.

In 2024, Cepheid (Danaher) partnered with the WHO to develop affordable POC TB and HIV diagnostic solutions for low-income regions.

Scope of Work – Global Point of Care Infectious Disease Market